Sutro Biopharma Stocks List


Recent Signals

Date Stock Signal Type
2019-03-18 ANAB Calm After Storm Range Contraction
2019-03-18 ANAB Upper Bollinger Band Walk Strength
2019-03-18 APVO Doji - Bearish? Reversal
2019-03-18 BTAI Pocket Pivot Bullish Swing Setup
2019-03-18 CTMX Narrow Range Bar Range Contraction
2019-03-18 CTMX 1,2,3 Retracement Bearish Bearish Swing Setup
2019-03-18 CTMX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-03-18 EQ Fell Below 20 DMA Bearish
2019-03-18 EQ 180 Bearish Setup Bearish Swing Setup
2019-03-18 NTGN 20 DMA Support Bullish
2019-03-18 SLS Calm After Storm Range Contraction
2019-03-18 STRO Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2019-03-18 ZYME Crossed Above 20 DMA Bullish
2019-03-18 ZYME 50 DMA Resistance Bearish

Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California, featuring clinical-stage drug discovery, development andmanufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is advancing next-generation oncology therapeutics through precision protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009. Mr. Newell has over 20 years of senior management experience in the biotechnology industry, and has worked for companies such as Aerovance, QLT, Inc., and Axys Pharmaceuticals, Inc. The CSO, Trevor Hallam, formerly worked at Palatin Technologies, AstraZeneca, SmithKline & French, Glaxo Group Research, and Roche Research Centre and Rhone-Poulenc Rorer. The CMO, Arturo Molina is a medical oncologist, who was most recently with J&J Innovation and was formerly with Cougar, Biogen Idec and the City of Hope Comprehensive Cancer Center. Shabbir Anik is the Chief Technical Operations Officer, formerly withOnyx/Amgen,Althea, Patheon, Neurex and Syntex.
The company has raised over $275m from Venture Investors, Collaborators and the Public Markets.
Sutro’s proprietary and integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+™, led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed antibody drugconjugates, or ADCs. STRO-001 is a potentially first-in-class ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin’s lymphoma, and is currently in a Phase I clinical trial. STRO-002 is a potentially best-in-class ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Sutro expects to commence a STRO-002 Phase 1 clinical trial focused on ovarian and endometrial cancers in early 2019.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
To date, Sutro’s drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Sutro’s platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.
In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next generationtherapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.

More about Sutro Biopharma